Literature DB >> 31786193

Therapeutic potentials of Apatinib in cancer treatment: Possible mechanisms and clinical relevance.

Nazila Fathi Maroufi1, Mohammad Reza Rashidi2, Vahid Vahedian3, Maryam Akbarzadeh4, Amir Fattahi5, Mohammad Nouri6.   

Abstract

Metastasis is one of the main issues in cancer treatment and it has been documented that angiogenesis plays an important role in this process. Studies showed that vascular endothelial growth factor (VEGF) and its receptor (VEGFR) have elevated expression in tumors and are involved in tumor progression and metastasis; suggesting their potential for being a therapeutic target. In this regard, Apatinib or YN968D1, a specific inhibitor of VEGFR-2 has been suggested as a promising therapeutic agent for cancer that can prevent tumor angiogenesis and metastasis. Furthermore, this drug can sensitize resistant tumor cells to chemotherapy drugs and increase the effectiveness of conventional chemotherapy drugs. Recent studies have shown that Apatinib has beneficial implications as a post-second and third-line therapy agent in a variety of cancers. Furthermore, Apatinib has the capacity to promote the overall survival and progression-free survival of cancer patients. This review discussed about, the molecular mechanisms and clinical relevance underlying the therapeutic potential of Apatinib in cancer treatment.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Apatinib; Cancer treatment; Vascular endothelial growth factor; Vascular endothelial growth factor receptor

Mesh:

Substances:

Year:  2019        PMID: 31786193     DOI: 10.1016/j.lfs.2019.117106

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  19 in total

1.  Comparative efficacy and adverse reactions of apatinib-chemotherapy combinations versus chemotherapy alone for treatment of advanced colorectal cancer: a meta-analysis of randomized controlled trials.

Authors:  Dengsheng Chen; Xinzhu Zhong; Lei Lin; Jiejie Xie; Yubao Lian; Luning Xu
Journal:  Am J Transl Res       Date:  2022-09-15       Impact factor: 3.940

Review 2.  Apatinib: A Novel Antiangiogenic Drug in Monotherapy or Combination Immunotherapy for Digestive System Malignancies.

Authors:  Haosheng Li; Haiyan Huang; Tao Zhang; Haoran Feng; Shaodong Wang; Yaqi Zhang; Xiaopin Ji; Xi Cheng; Ren Zhao
Journal:  Front Immunol       Date:  2022-06-29       Impact factor: 8.786

3.  Targeting ERK combined with apatinib may be a promising therapeutic strategy for treating oral squamous cell carcinoma.

Authors:  Tong-Chao Zhao; Si-Yuan Liang; Zhi-Hang Zhou; Wu-Tong Ju; Zhi-Yuan Zhang; Dong-Wang Zhu; Lai-Ping Zhong
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

4.  Treatment of malignant pleural effusion in non-small cell lung cancer with VEGF-directed therapy.

Authors:  Zhangqiang Xiang; Xiangyu Deng; Wenfeng He; Qian Yang; Laichao Ni; Marzieh Dehghan Shasaltaneh; Mazaher Maghsoudloo; Gang Yang; Jingbo Wu; Saber Imani; Qinglian Wen
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

5.  Apatinib sensitizes chemoresistant NSCLC cells to doxetaxel via regulating autophagy and enhances the therapeutic efficacy in advanced and refractory/recurrent NSCLC.

Authors:  Rong Hu; Tao Li; Kaiyuan Hui; Zi Chen; Nan Wang; Xingping Wu; Linyang Ge; Linfu Zhou
Journal:  Mol Med Rep       Date:  2020-09-07       Impact factor: 2.952

6.  αPD-1-mesoCAR-T cells partially inhibit the growth of advanced/refractory ovarian cancer in a patient along with daily apatinib.

Authors:  Juemin Fang; Na Ding; Xinling Guo; Yan Sun; Zhiwei Zhang; Bailu Xie; Zhong Li; Hui Wang; Wei Mao; Zhicai Lin; Fei Qin; Min Yuan; Wenqi Chu; Huanlong Qin; Qijun Qian; Qing Xu
Journal:  J Immunother Cancer       Date:  2021-02       Impact factor: 13.751

7.  Apatinib exhibits synergistic effect with pyrotinib and reverses acquired pyrotinib resistance in HER2-positive gastric cancer via stem cell factor/c-kit signaling and its downstream pathways.

Authors:  Beibei Su; Tingting Huang; Yu Jin; Han Yin; Hong Qiu; Xianglin Yuan
Journal:  Gastric Cancer       Date:  2020-10-08       Impact factor: 7.370

8.  Apatinib inhibits glioma cell malignancy in patient-derived orthotopic xenograft mouse model by targeting thrombospondin 1/myosin heavy chain 9 axis.

Authors:  Hui Yao; Jiangang Liu; Chi Zhang; Yunxiang Shao; Xuetao Li; Zhengquan Yu; Yulun Huang
Journal:  Cell Death Dis       Date:  2021-10-11       Impact factor: 8.469

9.  Apatinib combined with paclitaxel-based chemotherapy in patients with taxane-resistant advanced gastric cancer: a single-arm exploratory study.

Authors:  Shen Zhao; Nanfeng Fan; Hui Li; Jie Liu; Feng Huang; Yigui Chen; Min Zhou; Jiaqing Yu; Rongbo Lin
Journal:  Ann Transl Med       Date:  2020-10

Review 10.  Anlotinib: A Novel Targeted Drug for Bone and Soft Tissue Sarcoma.

Authors:  Shenglong Li
Journal:  Front Oncol       Date:  2021-05-20       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.